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Abstract 
Objective: Renal impairment in type 2 diabetes limits available glucose-lowering 
treatment options. This trial was conducted to establish the efficacy and safety of 
liraglutide as add-on to existing glucose-lowering medications in patients with 
inadequately controlled type 2 diabetes and moderate renal impairment. 
Research Design/Methods: In this 26-week, double-blind trial, 279 patients with HbA1c 
7-10%, BMI 20-45 kg/m2, and moderate renal impairment (eGFR 30-59mL/min/1.73m2; 
MDRD) were randomized (1:1) to  once-daily liraglutide 1.8 mg (n=140) or placebo 
(n=139). 
Results: The estimated treatment difference in HbA1c from baseline to week 26 was       
-0.66% [-7.25 mmol/mol] (95%CI -0.90 to -0.43] [-9.82 to -4.69 mmol/mol]; P<0.0001). 
Fasting plasma glucose decreased more with liraglutide (-1.22 mmol/L; [-22.0 mg/dL]) 
than with placebo (-0.57 mmol/L; [-10.3 mg/dL]) (P=0.036). There was a greater 
reduction in body weight with liraglutide (-2.41 kg) than with placebo (-1.09 kg) 
(P=0.0052). No changes in renal function were observed (eGFR relative ratio to 
baseline: -1% liraglutide; +1% placebo, estimated treatment ratio (ETR) 0.98, P=0.36). 
The most common adverse events were gastrointestinal side-effects (liraglutide 35.7%, 
placebo 17.5%). No difference in hypoglycemic episodes was observed between 
treatment groups (event rate/100 patient-years exposure: liraglutide, 30.47; placebo, 
40.08; P=0.54). The estimated ratio to baseline for lipase was 1.33 and 0.97 for 
liraglutide and placebo, respectively (ETR 1.37, P<0.0001). 
Conclusions:  Liraglutide did not affect renal function and demonstrated better glycemic 
control with no increase in hypoglycemia risk but with higher withdrawals due to GI 
adverse events than placebo in patients with type 2 diabetes and moderate renal 
impairment. 
  
Type 2 diabetes is the most prevalent cause of chronic kidney disease (CKD) that may 
progress to end-stage renal disease (dialysis and/or transplant) Diabetic nephropathy is 
the most likely cause of CKD especially associated with suboptimal glycemic control.  
Kidney function is categorized, based on estimated glomerular filtration rate (eGFR), (1). 
as: normal; mild; moderate; severe; end-stage. Stage 3 CKD (moderate renal 
impairment), defined as eGFR 30-59 mL/min/1.73m2, is further categorized as Stage 3a 
(eGFR 45-59 mL/min/1.73m2) and Stage 3b (30-44 mL/min/1.73m2) (1). In the USA, 
CKD (eGFR <60mL/min/1.73m2) occurs in approximately 20% of patients with type 2 
diabetes. (2). In the UKPDS, 28% of patients with type 2 diabetes developed renal 
impairment after a median of 15 years after diagnosis of diabetes (3). Impaired renal 
function is associated with increased cardiovascular risk which is further increased by 
poor glycemic control (1,4).  
 
Effective treatment of patients with type 2 diabetes and moderate renal impairment is 
challenging. Pharmacokinetic aspects of drugs cleared by the kidney can be influenced 
by renal impairment leading to the cessation or dosage reduction in many glucose-
lowering therapies (5-8) that may have reduced tolerability or increased safety risk in 
this population (9-12). 
 
Liraglutide, a once-daily human GLP-1 analog (13), is completely metabolized through a 
proteolytic mechanism and is not predominantly eliminated by a single organ (14). A 
single-dose (0.75 mg subcutaneously) pharmacokinetic trial with liraglutide provided 
initial evidence that the exposure to liraglutide was not increased in patients with all 
stages of renal impairment relative to patients with normal renal function (15). A meta-
analysis from the six Liraglutide Effect and Action in Diabetes (LEAD) trials has shown 
that the glycemic efficacy and safety of liraglutide (1.2 mg or 1.8 mg) in patients with 
mild renal impairment (eGFR 60-89 mL/min/1.73m2) was similar to those with normal 
renal function (16). 
 
The primary objective of this trial was to demonstrate the superiority of liraglutide 1.8 mg 
versus placebo as add-on to existing oral glucose-lowering agents and/or insulin 
therapy on glycemic control after 26 weeks’ treatment in patients with type 2 diabetes 
and moderate renal impairment (Stage 3 CKD) (Clinicaltrials.gov registry number: 
NCT01620489). 
 
Methods 
Trial Design 
This trial was conducted in order to provide efficacy and safety data in a population with 
moderate renal impairment and to update the label with this information. This 26-week 
randomized, double-blind, placebo-controlled, parallel-group trial was conducted 
between June 2012 and August 2013 and included patients from 78 sites: France (4 
sites), Poland (8), Russian Federation (15), Ukraine (6), UK (9), USA (36). 
Trial patients who met the eligibility criteria at screening were randomized (1:1), using a 
sponsor-provided telephone- or web-based randomization system, to receive once-daily 
subcutaneously-administered liraglutide or placebo. Trial site personnel, patients and 
sponsor remained blinded until trial completion. Stratification was based on the 
assessment of renal function (eGFR <45 or >45 mL/min/1.73m2 [Modification of diet in 
renal disease formula; MDRD]) using standardized creatinine measurements and insulin 
treatment (basal, premix or no insulin). Liraglutide or placebo were initiated with a 
starting dose of 0.6 mg/day, with subsequent weekly dose-escalations of 0.6 mg/day 
until the maintenance dose of 1.8 mg/day was reached (Supplemental Figure S1). At 
the discretion of the investigator, the dose escalation could have been extended up to 4 
weeks in case of gastrointestinal side-effects. Treatment was continued for a total of 26 
weeks with a 1-week follow-up period. For patients using insulin with an HbA1c <8% (64 
mmol/mol) at screening, the pre-trial insulin dose was reduced by 20% at Day 0 and 
kept fixed until the liraglutide dose escalation was complete. Titration to the pre-trial 
insulin dose was allowed at the discretion of the investigator. Patients were to maintain 
their background diabetes medication throughout the trial. Patients using either insulin 
or a sulfonylurea (SU) were allowed to reduce the dose of these agents if hypoglycemic 
episodes occurred.  
 
Trial Population 
Eligible trial patients were male/female, aged 18-80 years (inclusive) previously 
diagnosed with type 2 diabetes, had HbA1c 7-10% (53-86 mmol/mol;  inclusive) and on 
stable diabetes treatment for >90 days prior to screening. The following background 
diabetes treatments were allowed: monotherapy or dual therapy combinations of 
metformin and/or SU and/or pioglitazone; monotherapy with basal or premix insulin or 
any combination of basal or premix insulin with metformin and/or pioglitazone. The 
patient was to have moderate renal impairment >90 days prior to screening (confirmed 
at screening) and have a BMI of 25-45 kg/m2 (inclusive). 
 
Key exclusion criteria at screening included: hypoglycemic unawareness and/or 
recurrent severe hypoglycemia as judged by the investigator; impaired liver function 
(ALAT >2.5 upper limit of normal; ULN), history of chronic pancreatitis or idiopathic 
acute pancreatitis; New York Heart Association class IV heart failure; episode of 
unstable angina, acute coronary event, cerebral stroke/transient ischemic attack or 
other significant cardiovascular event within the past 180 days; a systolic blood 
pressure (SBP) >180 mmHg or a diastolic blood pressure (DBP) >100 mmHg; a 
screening calcitonin value >50 ng/L; and personal or family history of medullary thyroid 
carcinoma or multiple endocrine neoplasia syndrome type 2. 
 
The trial was conducted according to the Declaration of Helsinki (17) and the 
International Conference on Harmonization of Good Clinical Practice (18) principles. 
The protocol was reviewed and approved by the appropriate independent ethics 
committees or institutional review boards. All patients provided written informed consent 
prior to the commencement of any trial related activities. 
 
Assessments 
The primary efficacy endpoint was the change in HbA1c from baseline to Week 26. 
Responder endpoints, at Week 26, for HbA1c <7.0% (53 mmol/mol) and HbA1c <7.0% 
(53 mmol/mol) with no hypoglycemic episodes were determined. Change from baseline 
to Week 26 in fasting plasma glucose (FPG), body weight, BMI, SBP and DBP, fasting 
lipids and selected cardiovascular biomarkers were determined. 
 
The total prescribed daily insulin dose was recorded, summarized by visit and the ratio 
to baseline at week 26 was determined. 
 
Safety assessments included adverse events (AEs), change from baseline to Week 26 
in renal function (eGFR [MDRD] (19), urinary albumin:creatinine ratio [UACR]), 
amylase, lipase and pulse rate. UACR was calculated as the mean of the morning urine 
samples from the day before the visit and the day of the visit. 
 
Hypoglycemic episodes were categorized according to the ADA definition (<3.9 mmol/L; 
[70 mg/dL]) (20). Furthermore, a category of confirmed hypoglycemic events (subject 
unable to treat themselves (severe) and/or has a PG <3.1 mmol/L [56 mg/dL] or blood 
glucose <2.8 mmol/L [50 mg/dL] (minor)) was used in parallel with the ADA definition.  
 
Statistical Analyses 
Sample size was determined in order to demonstrate superiority of liraglutide versus 
placebo with regard to mean change in HbA1c using a significance level of 5% and a 
two-sided test. Assuming a mean difference of 0.4%, a standard deviation of 1.1%, 137 
evaluable patients per treatment arm were needed to achieve a power of 85%. All 
patients who received at least one dose of trial medication were included in the 
analyses. Descriptive statistics were used to summarize the data. The changes from 
baseline to Week 26 for primary and secondary continuous endpoints were analyzed 
using a mixed-model repeated measurement (MMRM) analysis. A model with treatment, 
country, stratification groups as factors and baseline HbA1c as a covariate, all nested 
within week, was used using an unstructured covariance matrix. Depending on 
distribution of data, a log transformation was used for some parameters before entering 
into the statistical model. For those, resulting estimated means were back-transformed 
to the original scale, giving estimates of treatment ratios instead of treatment 
differences. Dichotomous efficacy endpoints were analyzed using a logistic regression 
model. Frequencies were to be estimated for each treatment from the estimated odds 
for the corresponding treatment. The frequency for a treatment group was to be 
calculated as 100 x (estimate of treatment odds / (1+estimate of treatment odds). AEs 
were summarized descriptively. Confirmed hypoglycemic events were analyzed using a 
negative binomial regression model. 
 
Results 
Patient Disposition 
In total, 279 patients were randomized to receive either liraglutide 1.8 mg or placebo 
(140 and 139 patients, respectively) (Supplemental Figure S2). Two patients in the 
placebo group were not exposed to trial medication. . All remaining patients exposed to 
either liraglutide (140) or placebo (137) were included in the analysis sets. 
Approximately 25% of patients in each group withdrew from the trial. More patients in 
the liraglutide group withdrew due to AEs (19; 13.6%) than in the placebo group (4; 
2.9%). 
 Demographics and Baseline Characteristics 
Patient demographics and baseline characteristics were generally well-balanced 
between the two treatment groups (Table 1). The mean age of the liraglutide group  
appeared to be slightly higher than in the placebo group. Overall, 16.6% of patients 
were elderly (>75 years) and almost half (49.8%) were 65-74 years. The mean duration 
of diabetes was 15.9 years in the liraglutide group and 14.2 years in the placebo group. 
Approximately 55% of patients were taking background insulin medication at screening 
(basal insulin, 19.1%; premix insulin 36.1%). The mean BMI for all patients was 33.9 
kg/m2. The proportion of patients with Stage 3b CKD (eGFR [MDRD] 30-
<45mL/min/1.73m2) was approximately 43% in both treatment groups. 
 
Efficacy 
After 26 weeks of treatment, HbA1c was reduced more with liraglutide (-1.05% [-11.4 
mmol/mol] than with placebo (-0.38% [-4.18 mmol/mol]) (Figure 1A) with an estimated 
treatment difference (ETD) of -0.66% [-7.25 mmol/mol] (95%CI -0.90% to -0.43%; -9.82 
to -4.69 mmol/mol, P<0.0001). Sensitivity analyses, conducted post-hoc due to 
concerns on missing data, corroborated  the results from the MMRM analysis 
(Supplemental Table S1). A post-hoc subgroup analysis for the mean change in HbA1c 
from baseline to week 26 between Stage 3A and Stage 3B CKD indicated that 
liraglutide was as effective in reducing HbA1c in both groups (subgroup by treatment 
interaction p=0.4897). The ETD for Stage 3A CKD was -0.72% [-7.86 mmol/mol] 
(95%CI -1.03 to -0.41; -11.2 to -4.47 mmol/mol, P<0.0001). The ETD for Stage 3B CKD 
was -0.57% [-6.26 mmol/mol] (95%CI -0.94 to -0.21; -10.2 to -2.29 mmol/mol P=0.0022 
(Supplementary Table 5).(21) 
 
More patients achieved the ADA target of HbA1c <7.0% [<53 mmol/mol] with liraglutide 
(52.8%) than with placebo (19.5%) (Figure 1B). The estimated odds ratio (EOR) of 
achieving this target (liraglutide/placebo) was 4.64 (95%CI 2.54-8.46, P<0.0001). More 
patients achieved the composite target of HbA1c <7.0% [<53 mmol/mol] and no minor or 
severe hypoglycemic episodes with liraglutide (33.2%) than with placebo (11.2%). The 
EOR of achieving this target was 3.94 (95%CI 2.12-7.30, P<0.0001). Although not pre-
specified, the target analyses were performed with an HbA1c target of <7.5% since this 
may be more clinically relevant. The EOR of achieving HbA1c <7.5% [<58 mmol/mol] 
was 4.60 (95%CI 2.49-8.47, P<0.0001) and the EOR for the composite target was 3.72 
(95%CI 2.07-6.69, P<0.0001). 
 
Reductions in FPG were observed for both treatment groups (Figure 1C). The estimated 
mean change in FPG from baseline to Week 26 was -1.22 mmol/L (-22.0 mg/dL) with 
liraglutide and -0.57 mmol/L (-10.3 mg/dL) with placebo. The ETD was -0.65 mmol/L (-
11.6 mg/dL) (95%CI -1.25 to -0.04 mmol/L; -22.5 to -0.76 mg/dL, P=0.036). 
 
Both treatment groups exhibited a gradual weight reduction during the trial (Figure 1D). 
The patients in the liraglutide group had a greater reduction in body weight than the 
placebo group (-2.41 kg and -1.09 kg, respectively) with an  ETD of -1.32 kg (95%CI -
2.24 to -0.40 kg, P=0.0052). In addition, BMI was reduced more with liraglutide (-0.88 
kg/m2) than with placebo (-0.38 kg/m2) with an ETD of -0.51 kg/m2 (95%CI -0.83 to -
0.18 kg/m2, P=0.0022).  
The total daily insulin dose at week 26 decreased by 8% in the liraglutide group and by 
3% in the placebo group. The changes in the dose of sulfonylureas were not 
determined. 
 
From baseline to Week 26, there was no treatment difference observed for change in 
the fasting lipid profile (P-value range 0.21 to 0.81) (Supplementary Table S2). 
 
Several biomarkers were evaluated in order to assess the cardiovascular effects of 
liraglutide (Supplementary Table S3).  
 
SBP reduction occurred in both treatment groups (-2.45 mmHg with liraglutide; -0.33 
mmHg with placebo) but there was no difference between treatments (P=0.25). There 
was no difference between treatments in DBP (P=0.89). 
 
Safety 
Over the 26-week trial period, the overall incidence of AEs and serious AEs (SAE) was 
comparable between the two treatment groups (Table 2). The patients recovered from 
the AE/SAE with equal frequency between both treatment groups. A post-hoc analysis 
based on eGFR subgroup indicated that there was no difference in the percentage of 
subjects treated with liragutide who reported AEs (75.9% and 77.0% for Stage 3A and 
Stage 3B CKD, respectively; Supplementary Table 5).(21) The most common AEs 
reported with liraglutide were gastrointestinal (35.7%), which tended to resolve quickly, 
and the majority were considered mild in severity. However, for subjects in the 
liraglutide group who withdrew due to a GIAE (9 subjects; 11 events), the majority of 
AEs were either moderate (6 events) or severe (4 events). The most frequently reported 
gastrointestinal AEs were nausea (21.4%) and vomiting (12%). AEs within the 
gastrointestinal disorder and metabolism and nutrition disorders system organ classes 
are known side-effects of liraglutide and the GLP-1 receptor agonist class. The higher 
rates of these events reported in the liraglutide group were expected and were in line 
with previous results observed in the liraglutide clinical program. A post-hoc analysis 
based on eGFR subgroup indicated that there was a slight difference in the percentage 
of subjects treated liraglutide who reported GIAEs where more subjects with Stage 3A 
CKD (38.0%) reported these types of AEs than those with Stage 3B CKD (32.8%).(21) 
In the liraglutide group there was one SAE of renal impairment, and in the placebo 
group there was one SAE each for renal impairment and urethral stenosis. The number 
of SAE by eGFR subgroup were low (post-hoc); however, there was a trend of 
approximately twice as many SAEs in subjects with Stage 3B CKD (liraglutide 9 
subjects, [14.8%]; placebo 9 subjects [15.3%]) than in those with Stage 3A CKD 
(liraglutide 5 subjects [6.3%]; placebo 6 subjects [7.7%]).(21) There were five deaths in 
the trial; four in the liragutide group (diabetic ketoacidosis; cerebral hemorrhage; biliary 
sepsis; and cerebrovascular accident, pulmonary fibrosis, pulmonary edema, left 
ventricular failure and pneumonia [the last five terms for one patient]) and one in the 
placebo group (atherosclerosis) (Supplemental Table S4). The deaths were not 
clustered within a specific system organ class or eGFR stratum (liraglutide: 2 subjects 
Stage 3A stratum; 2 subjects Stage 3B stratum; placebo: Stage 3B stratum). The 
relationship to trial product was assessed by the investigator as unlikely for the four 
liraglutide cases and as possible for the placebo case. 
 
In the liraglutide group 20.7% of patients (97 episodes) and in the placebo group 26.3% 
(160 episodes) experienced documented symptomatic hypoglycemic episodes (20) 
(Figure 2A). One severe hypoglycemic episode was reported in a 46-year-old female 
treated with liraglutide who had a baseline HbA1c of 7.1% but did not reduce the insulin 
dose at randomization as advised by the protocol. The patient did not lose 
consciousness, but carbohydrates were administered by another person. In the 
liraglutide group, 5.7% of patients experienced a confirmed hypoglycemic event 
whereas 10.9% of patients in the placebo group experienced one, as estimated from a 
logistic regression model (P=0.076). No difference in event rates of confirmed 
hypoglycemic episodes were observed between the treatment groups (event-rate/100 
patient-years exposure: liraglutide 30.47, placebo 40.08; estimated treatment ratio 
(ETR)=0.76, 95%CI 0.31-1.84, P=0.54).  
 
Renal function was assessed as a safety parameter. There was no significant difference 
in ratio to baseline for serum creatinine between the treatment groups after 26 weeks 
(P=0.26). The mean observed change in eGFR (MDRD) from baseline to Week 26 
including last observation carried forward (LOCF) was -0.35 mL/min/1.73m2 in the 
liraglutide group and +0.37 mL/min/1.73m2 in the placebo group. The estimated ratio of 
week 26 to baseline for eGFR (MDRD) for the liraglutide group was 0.99 (-1%) and for 
the placebo group was 1.01 (+1%) (Figure 2B). The ETR of 0.98 (95%CI 0.94-1.02, 
P=0.36) indicated that liraglutide did not affect eGFR. The estimated ratio of Week 26 to 
baseline for UACR was 0.87 with liraglutide and 1.05 with placebo. The ETR of 0.83 
(95%CI 0.62-1.10, P=0.19) was not statistically significant. Overall, there was no 
difference seen in renal function parameters between treatment groups. 
 
At baseline, 12.9% and 16.8% of patients had an amylase ULN in the liraglutide and 
placebo groups, respectively. At Week 26, 20.0% and 20.2% of patients had an 
amylase ULN in the liraglutide and placebo groups, respectively. No amylase values 
3 ULN were observed in the trial. The mean observed change in amylase levels from 
baseline to Week 26 including LOCF was 9.10 U/L for the liraglutide group and -0.31 
U/L for the placebo group. The estimated ratio to baseline for amylase for the liraglutide 
group was 1.15 and for the placebo group was 1.01 (ETR 1.14, P<0.0001). 
 
In the liraglutide group, 31.4% of patients had a baseline lipase value >ULN and at 
Week 26, 48.6% of patients had a lipase >ULN (Figure 2C). Twenty-nine patients 
(27.6%) shifted from a normal lipase value at baseline to a high value at Week 26. 
Twenty-two patients (21.0%) had elevated lipase levels at baseline which remained 
elevated at Week 26. In the placebo group, 24.1% of patients had a baseline lipase 
value >ULN and at Week 26, 20.4% of patients had a lipase ULN. Seven patients 
(6.5%) shifted from normal lipase to a high value at Week 26. Fifteen patients (13.9%) 
had elevated lipase levels at baseline which remained elevated at Week 26. The mean 
observed change from baseline to Week 26 including LOCF was 18.97 U/L for the 
liraglutide group and -1.70 U/L for the placebo group. The estimated ratio to baseline for 
lipase in the liraglutide group was 1.33 and for the placebo group was 0.97 (ETR 1.37, 
P<0.0001). At Week 26, no patient treated with liraglutide, but one patient treated with 
placebo, had a lipase >3 ULN. None of the patients with either elevated amylase or 
lipase had clinical evidence of acute pancreatitis (Supplemental material for workup 
details).  
 
One non-serious AE of chronic pancreatitis was observed in the trial. A 72-year-old 
male with a duration of diabetes of 6.7 years (liraglutide group) had a history of elevated 
amylase and lipase levels for several years prior to trial entry but no clinical symptoms 
of pancreatitis. An ultrasound, performed due to elevated baseline lipase (>3 ULN) and 
amylase (>2 ULN) , showed diffuse changes in pancreatic parenchyma. The 
asymptomatic patient was diagnosed with chronic pancreatitis on Day 11 of treatment 
and was withdrawn. 
 
Mean pulse increased more with liraglutide (3.20 beats/min) than with placebo (0.23 
beats/min) (Figure 2D). This increase occurred by Week 2 and remained stable 
throughout the remainder of the trial. The ETD was 2.98 beats/min (95%CI 0.71-5.24, 
P=0.010). At Week 26, 30.2% of liraglutide patients and 23.6% of placebo patients had 
a >10 beats/min pulse increase from baseline. 13.2% and 9.1% of liraglutide and 
placebo patients, respectively, exhibited a >15 beats/min pulse increase from baseline 
whereas a small percentage (1.9% and 2.7%, respectively) had a >20 beats/min pulse 
increase from baseline. The percentage of patients with unchanged or decreased pulse 
at Week 26 was 23.6% (liraglutide) and 44.5% (placebo). 
 
Conclusions 
In patients with moderate renal impairment (eGFR 30-59 mL/min/1.73m2) and 
uncontrolled type 2 diabetes, addition of liraglutide to background glucose-lowering 
therapy produced clinically  meaningful reductions in HbA1c and FPG compared to 
placebo after 26 weeks of treatment. There was a greater percentage of responders in 
the liraglutide group compared to the placebo group for the dichotomous endpoints of: 
HbA1c below 7.0% (<53 mmol/mol) and HbA1c below 7.0% (<53 mmol/mol) and no 
hypoglycemic episodes. These results demonstrate that better glycemic control is 
achieved with liraglutide than with placebo in patients with type 2 diabetes and 
moderate renal impairment.  
 
Few clinical trials have reported results with a GLP-1 receptor agonist in patients with 
type 2 diabetes and moderate renal impairment (22). Results from an albiglutide active 
comparator-controlled (sitagliptin) trial in patients with mild (51.7%), moderate (41.0%) 
and severe (7.3%) renal impairment (eGFR >15 to <90 mL/min/1.73m2) (23) 
demonstrated that once-weekly albiglutide was more efficacious than sitagliptin. Like 
liraglutide, albiglutide is degraded by enzymatic catabolism (23) whereas exenatide (24) 
and lixisenatide (25) are eliminated by renal clearance. 
 
Patients with type 2 diabetes and renal impairment have an increased risk of 
cardiovascular events (4). Patients in this trial were obese thus increasing 
cardiovascular risk further. Liraglutide improved various cardiovascular markers 
compared to placebo. Patients treated with liraglutide lost more body weight than those 
treated with placebo and exhibited a greater reduction in BMI. There was a greater 
increase in pulse with liraglutide than with placebo. Approximately twice as many 
patients in the placebo group exhibited unchanged or decreased pulse compared to the 
liraglutide group. The long-term clinical effect of an increase in pulse has not yet been 
established. 
 
 
While the reductions in weight and SBP were similar to the LEAD trials, the ETD for the 
change in HbA1c from baseline was considerably lower. However, this trial population 
was older (68.0 and 66.3 years for the liraglutide and placebo groups, respectively) and 
had a longer duration of diabetes (15.9 and 14.2 years for the liraglutide and placebo 
groups, respectively) than those in the LEAD trials (age: 53.0-57.5 years; duration of 
diabetes 5.4-9.2 years.(26-32) 
 
It is of clinical relevance that there was no worsening of renal function in patients treated 
with liraglutide while on diverse background glucose-lowering therapy. Treatment 
differences were not observed in the Week-26 ratio to baseline for eGFR. The observed 
UACR as an indication of a patient’s albuminuria was 17% lower with liraglutide 
although not statistically significant. Albuminuria is not only a marker for kidney damage 
but it is also a cardiovascular risk factor (33,34).  
 
Patients with chronic kidney disease and diabetes are at increased risk of 
hypoglycemia, particularly when using insulin (35). A smaller percentage of patients 
treated with liraglutide experienced a hypoglycemic episode than those treated with 
placebo. There was a comparable risk in the event rate of hypoglycemia between both 
groups. Considering that more than half of the patients were treated with insulin, this  
supports that liraglutide does not increase the hypoglycemia risk in this population. 
 
Volume depletion events, such as nausea, vomiting and diarrhea, in patients with CKD, 
could, potentially, adversely affect kidney function (1). Even though more patients 
treated with liraglutide reported these types of events in this trial, most were mild in 
intensity and resolved quickly. There was one severe case of nausea and two of 
vomiting reported in the liraglutide group. In the LEAD 1-5 trials, the incidence of 
nausea, diarrhea and vomiting ranged from 6.8-40%, 7.9-18.7%, and 5-17%, 
respectively(26-32). Even though the number of patients with moderate or severe renal 
impairment was small in the meta-analysis of the LEAD trials, the patients taking 
liraglutide experienced nausea more frequently (21%) than those with normal renal 
function (12%) indicating that patients with renal impairment may experience more 
gastrointestinal effects when treated with liraglutide.(16) 
 
Compared to results from the albiglutide trial, the overall incidence of GIAE between 
daily liraglutide (35.7%) and once-weekly albiglutide (31.7%) was similar. However, the 
incidence of nausea and vomiting was higher with daily liraglutide (nausea 21.4%; 
vomiting 12.1%) than with once-weekly albiglutide (nausea 4.8%; vomiting 1.6%). 
These trials had different designs (active comparator- vs placebo-controlled) and 
different inclusion criteria (albiglutide included patients with eGFR ≥15-<90 
mL/min/1.73m2 [Stages 2-4 CKD]). (23) . Hydration status should be monitored if 
vomiting occurs in patients with impaired renal function who are receiving renin-
angiotensin system blocking agents and/or diuretics. 
 
Increases in serum amylase and lipase values, of unknown mechanism, have been 
seen previously with liraglutide and therefore routine monitoring of pancreatic enzymes 
was performed. Even though amylase was shown to be elevated more in the liraglutide 
group compared to the placebo group at Week 26, the median amylase value was 
below the ULN. Increases in lipase in the liraglutide group were seen as early as Week 
2. More patients shifted from a normal baseline lipase value to an elevated value at 
Week 26 with liraglutide than with placebo. The median lipase value in the liraglutide 
group at Week 26 was close to the ULN. However, the median baseline level of lipase 
seemed to be higher in this patient population with moderate renal impairment than 
observed in previous studies (36). Approximately 20% of patients with type 2 diabetes 
have elevated lipase levels (36). An association between eGFR reductions and elevated 
baseline lipase and amylase has been observed in patients with type 2 diabetes (37). 
Within Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome 
Results (LEADER) trial, 24% of patients (n=1840) with moderate renal impairment and 
12% of the patients (n=3417) with normal eGFR demonstrated elevated lipase levels at 
baseline (37). In this trial, approximately 20-30% of patients had elevated baseline 
lipase levels. However, since more patients treated with liraglutide had lipase elevations 
at the end of treatment than those with placebo, it is apparent that these elevations are 
not caused just by type 2 diabetes and renal impairment. Lipase and amylase increases 
have also been seen with other GLP-1 receptor agonists and DPP-4 inhibitors (38).  
 
The high withdrawal rate (~25%) in both treatment groups is a limitation of this trial. This 
trial investigated an older and frailer population, which might lead to more AEs, 
specifically gastrointestinal effects, being experienced by the patients. Several post-hoc 
sensitivity analyses, conducted due to concerns on missing data, supported the 
conclusions of the primary statistical method. Even though the withdrawal rate in both 
groups was similar, the reasons and timing were different. Patients treated with 
liraglutide tended to withdraw due to AEs, about half of which were gastrointestinal; 
whereas, those treated with placebo discontinued due to meeting withdrawal criteria, 
predominantly unacceptable hyperglycemia or changes in diabetes medication. Patients 
treated with liraglutide tended to withdraw earlier in the trial and due to GI side-effects, 
which corresponds to the AE patterns observed in other liraglutide trials. Subjects 
treated with placebo tended to withdraw later in the trial. Caution should be exercised if 
nausea or vomiting occurs in patients with moderate renal impairment to ensure proper 
evaluation if mild pancreatitis is suspected. The rather short duration of the trial does 
not allow predicting long-term glycemic responses.  
 The placebo-controlled design of this trial is another limitation. However, liraglutide was 
investigated as an add-on to a wide array of glucose-lowering medications including 
insulin. As such, we believe that placebo was the most appropriate comparator. 
 
An additional limitation for this trial is that stratification by eGFR was based on results at 
the screening visit even though eGFR was also assessed at the randomization visit. It is 
acknowledged that serum creatinine levels may have varied between the visits. 
Nonetheless, this would be as likely in both the liraglutide and the placebo groups and 
therefore, should not bias the results of the trial. 
 
Liraglutide did not affect renal function, demonstrated better glycemic control and weight 
reduction with no increase in hypoglycemia risk but with higher withdrawals due to GI 
adverse events than placebo in patients with type 2 diabetes and moderate renal 
impairment. 
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Table 1 Demographic and baseline characteristics 
 Liraglutide 1.8 mg 
(N=140) 
Placebo 
(N=137) 
Sex, n, (%) 
Female  
Male 
 
65 (46.4) 
75 (53.6) 
 
72 (52.6) 
65 (47.4) 
Age, years, mean (SD) 68.0 (8.3) 66.3 (8.0) 
Age group, n (%) 
18-64 years 
65-74 years 
>75 years 
 
38 (27.1) 
72 (51.4) 
30 (21.4) 
 
55 (40.1) 
66 (48.2) 
16 (11.7) 
Duration of diabetes, years, mean (SD) 15.9 (8.9) 14.2 (7.5) 
Race, n (%) 
White 
Black or African American 
Asian non-Indian 
Asian Indian 
Native Hawaiian or other Pacific Islander 
Other 
 
123 (87.9) 
14 (10.0) 
2 (1.4) 
1 (0.7) 
0 
0 
 
129 (94.2) 
4 (2.9) 
1 (0.7) 
0 
1 (0.7) 
2 (1.5) 
Insulin treatment, n (%) 
Basal 
Premix 
No insulin 
 
29 (20.7) 
48 (34.3) 
63 (45.0) 
 
24 (17.5) 
52 (38.0) 
61 (44.5) 
Total daily insulin dose, Geo mean (CV) 47.1 (0.70) 50.8 (0.85) 
Oral glucose-lowering therapies, n (%) 
Metformin 
SU 
 
14 (10.0) 
15 (10.7) 
 
12 (8.8) 
19 (13.9) 
Pioglitazone 
Metformin + SU 
Repaglinide* 
Metformin + pioglitazone 
SU + pioglitazone 
MET+SU fixed combination* 
Metformin + SU + pioglitazone 
Metformin + SU + acarbose* 
1 (0.7) 
26 (18.6) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
25 (18.2) 
0 (0.0) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
0 (0.0) 
0 (0.0) 
HbA1c %, mean (SD) 
mmol/mol, mean (SD) 
8.08 (0.792) 
64.8 (8.66) 
8.00 (0.853) 
63.9 (9.33) 
FPG mmol/L, mean (SD)  
mg/dL, mean (SD) 
9.48 (3.270) 
170.83 (58.92) 
9.27 (2.842) 
167.03 (51.21) 
Body Weight, kg, mean (SD) 93.63 (17.41) 95.63 (17.65) 
BMI, kg/m
2
, mean (SD) 33.4 (5.4) 34.5 (5.4) 
eGFR (mL/min/1.73m
2
), geo mean (CV) 45.4 (0.23) 45.5 (0.25) 
eGFR (mL/min/1.73m
2
), N (%) 
30- <45 
45-59 
>59 
 
61 (43.6) 
78 (55.7) 
1 (0.7) 
 
59 (43.1) 
78 (56.9) 
0 (0.0) 
Urinary albumin:creatinine ratio (mg/g), geo mean (CV) 55.5 (7.58) 69.8 (5.75) 
Blood pressure, mm Hg, mean (SD) 
Systolic 
Diastolic 
 
135.2 (14.8) 
77.2 (9.8) 
 
136.8 (14.4) 
78.1 (9.3) 
Hypertension, % patients at screening 90.0 88.3 
*combination of background medication not allowed according to the protocol 
SD=standard deviation; geo mean= geometrical mean; CV=coefficient of variance 
  
Table 2 Summary of Treatment Emergent Adverse Events 
Event Liraglutide 1.8 mg Placebo 
N % E N % E 
Adverse events 107 76.4 365 94 68.6 341 
Mild 89 63.6 242 77 56.2 218 
Moderate 47 33.6 98 50 36.5 109 
Severe 17 12.1 25 8 5.8 14 
Serious adverse events 14 10.0 21 15 10.9 20 
Possibly or probably related 65 46.4 157 37 27.0 88 
Gastrointestinal 40 28.6 86 12 8.8 23 
Fatal 4 2.9 8* 1 0.7 1 
Leading to withdrawal 19 13.6 26 4 2.9 6 
Gastrointestinal 9 6.4 11 1 0.7 1 
Frequently reported AE        
Gastrointestinal disorders 50 35.7 115 24 17.5 47 
Nausea 30 21.4 39 6 4.4 10 
Mild 22 15.7 26 6 4.4 9 
Moderate 10 7.1 12 1 0.7 1 
Severe 1 0.7 1 0 0 0 
Vomiting 17 12.1 18 3 2.2 4 
Mild 8 5.7 9 1 0.7 2 
Moderate 7 5.0 7 2 1.5 2 
Severe 2 1.4 2 0 0 0 
Diarrhea 10 7.1 13 4 2.9 6 
Mild 8 5.7 9 2 1.5 2 
Moderate 3 2.1 4 2 1.5 4 
Constipation 8 5.7 9 2 1.5 2 
Mild 7 5.0 8 2 1.5 2 
Moderate 1 0.7 1 0 0 0 
Investigations 38 27.1 61 33 24.1 55 
Increased amylase 3 2.1 3 4 2.9 4 
Increased lipase 21 15.0 23 12 8.8 13 
Glomerular filtration rate 
decreased 
9 6.4 10 7 5.1 14 
Infections and infestations 29 20.7 34 35 25.5 46 
Nasopharyngitis 7 5.0 7 16 11.7 17 
Upper respiratory tract 
infection 
4 2.9 4 7 5.1 8 
Nervous system disorders 20 14.3 25 11 8.0 36 
Headache 7 5.0 8 4 2.9 8 
Renal and urinary disorders 13 9.3 13 16 11.7 19 
Renal impairment 7 5.0 7 8 5.8 8 
Cardiac Disorders 5 3.6 8 4 2.9 6 
*One patient had 5 SAEs listed as fatal 
N=number of patients; E=number of events 
 
  
  
 
 
 
Figure 1 A: Estimated means plot (+ SE) of HbA1c (%) by treatment week and change from baseline to 
week 26. B: Responder endpoints for HbA1c <7.0%, HbA1c <7.5%,HbA1c <7.0% and no minor or severe 
hypoglycemic episodes and HbA1c <7.5% and no minor or severe hypoglycemic episodes at week 26. C: 
Estimated means plot (+ SE) of fasting plasma glucose (mmol/L) by treatment week and change from 
baseline to week 26. D: Estimated means plot (+ SE) of body weight (kg) by treatment week and change 
from baseline to week 26. Black circle/black bar liraglutide 1.8 mg; white square/white bar placebo 
 
 
 
  
 
 
 
 
 
Figure 2-A: Summary of ADA defined hypoglycemia (severe: patient unable to treat themselves; 
documented symptomatic: PG <3.9 mmol/L [70 mg/dL]; asymptomatic: PG< 3.9 mmol/L [70 mg/dL]; 
relative: symptomatic and PG >3.9 mmol/L [70 mg/dL[). B: Estimated means plot of eGFR (MDRD 
formula) by treatment week and ratio to baseline at week 26. C: Estimated means plot of lipase (U/L) by 
treatment week and ratio to baseline at week 26. D: Estimated means plot (+ SE) of pulse (beats/min) by 
treatment week and estimated means change from baseline to week 26. Black circle/black bar liraglutide 
1.8 mg; white square/white bar placebo 
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Principal Investigators 
 
The following is a list of principal investigators for each site that randomized patients: 
 
France: Jean-Paul Donnet, Gerard Fradet, Isidore Hochner, Véronique Kerlan;  
Poland: Małgorzata Arciszewska, Janusz Gumprecht, Monika Łukaszewicz, Magdalena Olszanecka-
Glinianowicz, Jarosław Opiela, Lucyna Ostrowska, Danuta Pupek-Musialik, Andrzej Stankiewicz;  
Russia: D. Alpenidze, I. Demidova, M. Kunitsina, T. Lysenko, N. Petunina, G. Reshedko, T. Rodionova, 
Ruslan Sardinov, M. Sergeeva-Kondrachenko, Minara Shamkhalova, F. Valeeva, N. Verbovaya, Natalia 
Vorohobina, L. Zarutskaya, L. Zhukova;  
Ukraine: Viktoriia Chernikova, Vadym Korpachev, Borys Mankovsky, Larysa Pererva, Liubov Sokolova, 
Maryna Vlasenko;  
UK: Stephen Atkin, Stephen Bain, Melanie Davies, Graham Hitman, David Hopkins, Andrew Johnson, 
John McKnight, Graham Leese, Frank Raymond; 
USA: Giovanni Baula, Jill Beavins, Gary Bedel, William Bestermann, William Biggs, Kenneth Blaze, Anna 
Chang, Ronald Chochinov, James Chu, Kenneth Cohen, Jonathan Condit, George Dailey, Peter 
Gagianas, Geetha Gopalakrishnan, Mitzie Hewitt, John Hoekstra, Patricia Houser, Eli Ipp, Richard 
Jackson, James Lane, Andrew Lewin, Barry Lubin, John Nicasio, Robert Pearlstein, Jeffrey Pollock, John 
Reed, Joseph Risser, Jeffery Rothman, David Scott, Jean Louis Selam, Yshay Shlesinger, Robert Silver, 
Ronald Stegemoller, Ileana Tandron, Mark Warren, Albert Weisbrot. 
  
Workup to Assess Possible Cases of Pancreatitis 
The investigator was to ensure that subjects were informed of the characteristic symptoms of 
acute pancreatitis as part of the informed consent process. Confirmed cases of pancreatitis 
were to be followed-up with investigations of other potential causes (tests such as gallbladder 
ultrasound, triglycerides, liver enzymes, detailed history of concomitant medications or alcohol 
were suggested for follow up as part of the Investigators considerations relative to local 
standards of practice). If the investigator suspected acute pancreatitis, all suspected drugs were 
to be discontinued until confirmatory tests were conducted and appropriate treatment initiated. 
Subjects diagnoses with acute pancreatitis (as a minimum 2 of 3: characteristic abdominal pain, 
amylase and/or lipase >3UNR or characteristic findings on CT scan /MRI) were to be 
withdrawn from the study. 
 
  
 Table 1 Change in HbA1c (%) from Baseline to Week 26 from Post-hoc Sensitivity Analyses 
 N 
 
Change at  
week 26 (%) 
ETD 95% CI CI width p-value 
 Lira Placebo Lira Placebo 
Primary 
analysis 
(MMRM) 
127 136 -1.05 -.038 -0.66 -0.90; -0.43 0.47 <0.0001 
ANCOVA 
LOCF 
135 136 -1.07 -.038 -0.69 -0.89; -0.50 0.39 <0.0001 
Simple imputation post-hoc sensitivity analysis 
Unmodified 
BOCF 
140 137 -0.86 -0.28 -0.58 -0.76; -0.39 0.37 <0.0001 
BOCF and 
LOCF 
140 137 -1.04 -0.37 -0.66 -0.86; -0.47 0.39 <0.0001 
Multiple imputation post-hoc sensitivity analyses 
Placebo MI 140 137 -0.92 -0.39 -0.53 -0.75; -0.32 0.43 <0.0001 
Differentiated 
MI 
140 137 -1.01 -0.39 -0.62 -0.84; -0.40 0.44 <0.0001 
Data are estimates from MMRM (primary analysis) and ANCOVA (sensitivity analyses) models with 
treatment, country and stratification group as fixed factors and the baseline value as covariate. N: number 
of subjects contributing to the analysis. ANCOVA: analysis of covariance. BOCF: baseline observation 
carried forward. CI: confidence interval. CI width: upper minus lower CI limit. ETD: estimated treatment 
difference. Lira: liraglutide. LOCF: last observation carried forward. MI, multiple imputation. MMRM: mixed 
model for repeated measurement.  
  
 
Table 2 Observed Fasting Lipids at Baseline and at Week 26 (LOCF) and Estimated Treatment Ratio  
 
 Total 
cholesterol 
(mmol/L), 
mean (SD) 
LDL 
cholesterol 
(mmol/L), 
mean (SD) 
VLDL 
cholesterol 
(mmol/L), 
mean (SD) 
HDL 
cholesterol 
(mmol/L), 
mean (SD) 
Trigylcerides 
(mmol/L), 
mean (SD) 
Free fatty 
acids 
(mmol/L), 
mean (SD) 
Liraglutide, 
Week 0 
4.67 (1.24) 2.48 (1.05) 1.01 (0.52) 1.15 (0.30) 
2.32 
(1.50) 
0.86 (0.41) 
Liraglutide 
Week 26 (LOCF) 
4.62 (1.34) 2.49 (1.08) 0.91 (0.53) 1.19 (0.35) 
2.09 
(1.39) 
0.80 (0.34) 
Placebo 
Week 0 
4.74 (1.27) 2.52 (1.06) 1.00 (0.74) 1.20 (0.31) 
2.33 
(2.46) 
0.89 (0.42) 
Placebo 
Week 26 (LOCF) 
4.59 (1.31) 2.43 (1.12) 0.87 (0.43) 1.25 (0.32) 
1.99 
(1.12) 
0.82 (0.35) 
Estimated 
treatment ratio* 
(95%CI) 
p 
1.02 
(0.97; 1.08) 
0.4611 
1.06 
(0.97; 1.15) 
0.2082 
0.97 
(0.88; 1.06) 
0.4658 
0.99 
(0.94; 1.05) 
0.8101 
0.97 
(0.88; 1.07) 
0.5683 
1.02 
(0.90; 1.16) 
0.7132 
LOCF, last observation carried forward; SD, standard deviation; LDL, low density lipoprotein; VLDL, very 
low density lipoprotein; HDL, high density lipoprotein; *estimated treatment ratio=estimated ratio to 
baseline for liraglutide/estimated ratio to baseline for placebo (statistical analysis performed on log scale). 
 
  
  
Table 3 Cardiovascular Biomarkers at Week 26 
 
Biomarker Liraglutide 1.8 mg Placebo 
hs-CRP   
ratio to baseline, estimated means 0.82 1.08 
estimated treatment ratio (lira/placebo) 
(95% CI), p 
0.76 
(0.61; 0.96), 0.0220 
BNP   
ratio to baseline, estimated means 0.83 1.07 
estimated treatment ratio (lira/placebo) 
(95% CI), p 
0.78 
(0.63; 0.97), 0.0273 
PAI-1   
ratio to baseline, estimated means 1.10 0.98 
estimated treatment ration (lira/placebo) 
(95% CI), p 
1.13 
(0.96; 1.32) 0.1413 
 
 
 
Table 4 Details of Fatal Events 
 
Treatment 
group 
Sex 
Age 
(yrs) 
Duration 
of 
diabetes 
(yrs) 
Pertinent Medical History 
Strata 
(eGFR 
[mL/min/1.73 m
2
]; 
insulin) 
Days of 
Exposure 
Preferred 
term(s) of fatal 
event 
Causality to 
trial 
medication* 
Liraglutide Male 65 5.6 
Significant CV disease; 
cerebral ischemia; hepatic 
steatosis; prostatic 
adenoma 
>45; premix 125 
Diabetic 
ketoacidosis 
Unlikely 
Liraglutide Male 73 21.6 CV disease; hyperlipidemia >45; basal 139 
Cerebral 
hemorrhage 
Unlikely 
Liraglutide Male 70 32.5 
CV disease; chronic 
pulmonary disease; sleep 
apnea; depression 
<45; premix 131 Biliary sepsis 
Unlikely 
Liraglutide Female 79 17.3 
CV disease; pacemaker; 
conductive heart disease; 
hypertension; 
musculoskeletal disorder; 
osteoarthritis 
<45; basal 33 
Cerebrovascular 
accident; 
pulmonary 
fibrosis; 
pulmonary 
edema; left 
ventricular 
failure; 
pneumonia 
Unlikely 
Placebo Male 74 26.9 
CV disease; myocardial 
infarctions; congestive heart 
failure; hyperlipidemia; 
transient ischemia attacks; 
cerebrovascular accident 
<45; premix 116 Arteriosclerosis 
Possible 
*Causality was assessed by the investigator; eGFR estimated glomerular filtration rate. 
 
  
Table 5 Efficacy and Safety by eGFR strata and for the overall trial 
 
Stage CKD 
(eGFR Subgroup) 
Stage 3 CKD 
(30-59 mL/min/1.73 m2) 
Stage 3b CKD 
(30-<45 mL/min/1.73 m2) 
Stage 3a CKD 
(45-59 mL/min/1.73 m2) 
Treatment Group Lira 
n=140 
PBO 
n=137 
Lira 
n=61 
PBO 
n=59 
Lira 
n=79 
PBO 
n=78 
HbA1c, BL, mean % 
(SD) 
8.08 
(0.79) 
8.00 
(0.85) 
8.09 
(0.81) 
8.06 
(0.92) 
8.07 
(0.78) 
7.95 
(0.80) 
Change from BL at Week 26, 
estimated means 
-1.05 -0.38 -0.97 -0.40 -1.10 -0.38 
Treatment difference, estimated; 
p-value 
-0.66 
p<0.0001 
-0.57 
p=0.0022 
-0.72 
p<0.0001 
Subgroup by treatment interaction na p=0.4897 
AE, % subjects 76.4 68.6 77.0 78.0 75.9 61.5 
SAE, % subjects 10.0 10.9 14.8 15.3 6.3 7.7 
GI AE, % subjects 35.7 17.5 32.8 20.3 38.0 15.4 
BL, baseline; AE, adverse events; SAE, serious adverse events; GI AE, gastrointestinal adverse events 
  
 
 
Figure S1 Trial design 
 
  
  
 
Figure S2 Consort Flow diagram 
 
Protocol Amendments 
 
There were 1 global and 7 local substantial protocol amendments to the final protocol (dated 09-April-
2013). Protocol amendments were approved according to local requirements prior to implementation. 
Table 3 List of Substantial Protocol Amendments 
Amendment 
number 
Issue date Timing of 
change 
(before/after 
FSFV) 
Countries 
affected 
Key changes 
1 27 FEB 2012 Before United 
States  
Pregnancies in partners of trial subjects 
to be reported 
2 06 SEP 2012 After France Opening of new sites 
3 18 SEP 2012 After Poland Opening of new sites 
4 04 OCT 2012 After France Opening of new sites 
5 14 NOV 2012 After France Opening of new sites 
6 02 JAN 2013 After United 
States 
Change of text in Section 21 regarding 
FDA 1572 form 
7 27 NOV 2012 After Poland Opening of new sites 
8 09 APR 2013 After Global Changes to Table of contents, List of 
abbreviations, Section 6.4 Withdrawal 
criteria, Section 8.1 Visit procedures, 
Section 8.7 Assessments for safety, 
Section 9.1 Trial products, Section 12.3 
Follow-up of adverse events, Section 
14 Monitoring procedures, Section 17.3 
Statistical Analysis of Primary endpoint, 
Appendix B, Master SI/IC Version 2.0 
Section 1.5, SI/IC Version 1.0 
Additional assessment for subjects with 
confirmed abnormality of the C-cells 
introduced. 
FSFV=first subject first visit 
 
The primary change in the US substantial amendment 1 (27 Feb 2012) was per an FDA request on Dec 
9, 2011. Language was added in protocol section 12.4, Pregnancy to include if subjects or their partners 
become pregnant during the trial. Additionally, a pregnant partner consent form was written. 
Changes in US substantial amendment 6 (02 Jan 2013) included one change made in protocol section 
21, Critical documents, to clarify who should fill out the FDA 1572 form. In addition, errors were found in 
previously approved US local substantial amendment no. 1 dated 27 Feb 2012. The section numbers 
were incorrectly identified in amendment no. 1 as sections 12.4 and 12.4.1. This was corrected to 
sections 12.5 and 12.5.1 in the current amendment. 
Global substantial protocol amendment number 8 (09 Apr 2013) included the following updates: 
 Inclusion of RET gene testing upon granted informed consent and according to local law. The 
main reason for this global substantial protocol amendment was to allow for genetic testing of 
subjects with C-cell abnormality confirmed by pathology reports (medullary thyroid carcinoma 
[MTC] or C-cell hyperplasia). The subjects were to be asked to consent to have an additional 
blood sample taken to identify germline RET gene mutations associated with multiple endocrine 
neoplasia 2 (MEN2) syndrome. The genetic testing was only performed if consent had given by 
the subject and if allowed according to local law. 
 Update to Protocol Section 12.3 Follow-up of adverse events. A minor mistake in the protocol 
template was corrected. 
 Update to Protocol Section 17 Statistical Considerations. Based on consistent FDA feedback on 
use of LOCF in clinical trials in general, the statistical analyses section had been revised so that 
the primary statistical analysis will be performed using a mixed model for repeated measurements 
(MMRM), whereas ANCOVA using LOCF will be performed as described as a sensitivity analysis. 
 General administrative and editorial updates. In addition, a few minor inconsistencies were 
discovered which were corrected to ensure correct interpretation of the trial protocol. This 
included an update of Appendix B. 
 Update of master subject information/informed consent (SI/IC) and introduction of an additional 
SI/IC for subjects with confirmed C-cell abnormality. The master SI/IC was updated to reflect the 
possibility of genetic testing in case of thyroid surgery during the trial and an additional SI/IC was 
introduced to be obtained only from subjects with confirmed C-cell abnormality. 
The remaining 5 local substantial amendments allowed for opening of new sites. 
 
